Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
48.42
-0.25 (-0.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Sanofi-Aventis S.A. ADR
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
25
26
Next >
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
February 03, 2023
The major indexes continued to run despite mixed-to-weak earnings.
Via
Investor's Business Daily
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
February 03, 2023
Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony...
Via
Benzinga
Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples
February 03, 2023
Regeneron beat forecasts despite wide declines. But Sanofi fell on its mixed report.
Via
Investor's Business Daily
Earnings Outlook For Sanofi
February 02, 2023
Via
Benzinga
Hopeful Golden Cross Forms On Sanofi's Chart
January 26, 2023
Via
Benzinga
What Does Sanofi's Debt Look Like?
January 06, 2023
Over the past three months, shares of Sanofi Inc. (NASDAQ:SNY) increased by 20.92%. Before having a look at the importance of debt, let's look at how much debt Sanofi has.
Via
Benzinga
Sanofi Forecasts Foreign Exchange, Record Flu Vaccine Sales To Boost Q4 Earnings
January 04, 2023
Via
Benzinga
Nasdaq Futures Deflate As Apple Leads Tech Disappointments: Traders Look To Jobs Data For Mitigating Impact
February 03, 2023
Trading in the U.S. index futures suggests stocks may end a solidly positive week on a negative note. That said, the data-dependency of the Fed places the onus of providing trading cues to each...
Via
Benzinga
Sanofi Expects Moderate 2023 Profit Growth On Dupixent Demand, But Dampened By Aubagio Generics Competition
February 03, 2023
Via
Benzinga
Alphabet, Apple And 3 Stocks To Watch Heading Into Friday
February 03, 2023
With Nasdaq stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
Fear & Greed Index Remains In 'Greed' Zone As Nasdaq Record Sharp Gains For Fourth Straight Week
February 03, 2023
The CNN Money Fear and Greed index showed some decline in overall sentiment among US investors. US stocks closed mostly higher on Thursday, with the tech-laden Nasdaq index leading the rally. Investors...
Via
Benzinga
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
January 31, 2023
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...
Via
Benzinga
Sanofi Layoffs 2023: What to Know About the Latest SNY Job Cuts
January 31, 2023
One French pharmaceutical producer is implementing job cuts. Here's what investors need to know about the Sanofi layoffs.
Via
InvestorPlace
Sanofi Might Pull Down Shutters For Two Vaccine Plants In India
January 30, 2023
After Sanofi SA (NASDAQ: SNY) failed to secure a UNICEF contract, the company is weighing closing operations at two of its vaccine-making facilities in Hyderabad, India, and plans to let go of all...
Via
Benzinga
Europe Approves Regeneron-Sanofi's Dupixent For Expanded Use In Eosinophilic Esophagitis
January 30, 2023
Via
Benzinga
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
January 29, 2023
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed.
Via
Benzinga
Could This Vaccine Become Sanofi's Latest Blockbuster?
January 29, 2023
This vaccine candidate could be approved in newborns and infants later this year.
Via
The Motley Fool
7 Blue-Chip Stocks to Buy as a New Bull Market Emerges
January 26, 2023
Many blue-chip stocks look like a bargain right now, and these seven companies are certainly no exception.
Via
InvestorPlace
Wall Street Thinks These 2 Blazing Healthcare Stocks Could Have 21% to 30% Upside in 2023
January 23, 2023
It's difficult to imagine a future where healthcare isn't in high demand.
Via
The Motley Fool
Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market
January 19, 2023
After years of lab failures, the companies could crack open a multibillion-dollar market.
Via
Investor's Business Daily
The Viral “Tripledemic” Opportunity
January 14, 2023
Between Covid, the flu, and RSV, investors in over-the-counter consumer pharmaceutical companies might be wondering if now is a logical time to up their holdings in the companies that make cold and flu...
Via
Talk Markets
Johnson & Johnson Cuts Production, Ends Contracts For Not So Successful COVID-19 Shot
January 13, 2023
Johnson & Johnson (NYSE: JNJ) has significantly scaled back its efforts of manufacturing its COVID-19 vaccine after facing a fall in demand.
Via
Benzinga
Sanofi Opts To Terminate Rare Disease Program With Regulus Therapeutics
January 09, 2023
Via
Benzinga
What This Drug News Could Mean for Sanofi Shareholders
January 08, 2023
This star drug for Sanofi is one step closer to approval in the European Union for another chronic inflammatory disease.
Via
The Motley Fool
5 Top Pharma Stocks of 2022 to Buy for the Long Haul
January 06, 2023
The biggest drug company blockbusters bring in billions of dollars, which is one of the reasons to consider these top Pharma stocks.
Via
InvestorPlace
FDA Permits Pharmacies To Distribute Abortion Pills, Tesla's Aggressive Discounting May Have Hit Gross Margins, Goldman Sachs Bullish On M&A Activity In Late 2023: Top Stories Today
January 04, 2023
Reuters Goldman Sachs Bullish On M&A Deals Activity Picking Up In Late 2023
Via
Benzinga
Could This Drug News Give a Lift to Eli Lilly Stock?
January 01, 2023
In November, Eli Lilly received positive news from the U.S. Food and Drug Administration.
Via
The Motley Fool
3 Medical Dividend Stocks That Hit the Sweet Spot
December 26, 2022
These three offer high dividend yields and consistent revenue growth.
Via
The Motley Fool
After Five Years Of Collaboration, Sanofi & Innate Pharma Expand Oncology Pact With Additional Programs
December 19, 2022
Via
Benzinga
Market Rally Pressured On Fed Rate Outlook; Moderna, Boeing, Tesla In Focus: Weekly Review
December 16, 2022
Moderna spiked on a cancer vaccine while Tesla continued to dive.
Via
Investor's Business Daily
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
25
26
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.